F S&P 500
5,240.75 +1.75 (+0.03%) F Dow Jones
39,566.00 +30.00 (+0.08%) F Nasdaq
18,215.25 +0.75 (+0.00%) E-mini Russell 2000 Index Futur
2,084.90 +0.80 (+0.04%) Petróleo
79.68 +0.42 (+0.53%) Oro
2,355.80 +15.50 (+0.66%)
BioCorRx Inc. (BICX)
BioCorRx Inc.
2390 East Orangewood Avenue
Suite 500
Anaheim, CA 92806
United States
714 462 4880
https://www.biocorrx.com
Sector(es): Healthcare
Industria: Medical Care Facilities
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Lourdes Felix | CEO, CFO & Director | 250k | N/D | 1968 |
| Mr. Louis Charles Lucido | President & Director | 60k | N/D | 1948 |
| Dr. George N. Fallieras | Medical Consultant | N/D | N/D | N/D |
Descripción
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program for substance abuse that includes peer recovery support; and distributes UnCraveRx weight loss management program, a medically assisted weight management program. The company is also developing BICX101, an injectable and implantable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
Gestión corporativa
La calificación ISS Governance QuickScore de BioCorRx Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
